Trial Profile
Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2019
Price :
$35
*
At a glance
- Drugs Daxibotulinumtoxin A (Primary)
- Indications Torticollis
- Focus Therapeutic Use
- Sponsors Revance Therapeutics
- 09 Oct 2018 Results presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
- 21 Jun 2018 Primary endpoint has been met. (Improvement of dystonia as measured by change from baseline in Toronto Western Spasmodic Torticollis Rating Scale), according to a Revance Therapeutics media release.
- 24 May 2018 Results presented in a Revance Therapeutics Media Release.